12305e97-f72f-4de7-9735-4cdbecb60296
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.500
- WNT_BETA_CATENIN_SIGNALING+0.400
- ANGIOGENESIS+0.300
- APICAL_JUNCTION+0.300
- APICAL_SURFACE+0.300
- COAGULATION+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- KRAS_SIGNALING_DN+0.300
- MYOGENESIS+0.300
- ESTROGEN_RESPONSE_EARLY+0.200
Top 10 suppressed
- E2F_TARGETS-0.600
- PROTEIN_SECRETION-0.600
- G2M_CHECKPOINT-0.500
- MTORC1_SIGNALING-0.500
- INTERFERON_ALPHA_RESPONSE-0.400
- INTERFERON_GAMMA_RESPONSE-0.400
- MYC_TARGETS_V1-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.400
- ANDROGEN_RESPONSE-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R116 | — | — | 0.912 |
| 2 | TCGA-MP-A4TD-01A-32R-A262-07 | — | cohortA3 | 0.893 |
| 3 | X9cad7a78.ea9b.47b0.9d06.e5e696031cc3 | — | cohortA1 | 0.888 |
| 4 | 20050037.TNBC | — | C | 0.872 |
| 5 | SRR1516073 | — | — | 0.871 |
| 6 | TCGA-A7-A426-01A-22R-A24H-07 | — | A | 0.867 |
| 7 | TCGA-BH-A28O-01A-11R-A22K-07 | — | A | 0.864 |
| 8 | TCGA-BH-A42V-01A-11R-A24H-07 | — | A | 0.863 |
| 9 | MBCProject_0003_T2_RNA | — | A | 0.860 |
| 10 | R37 | — | — | 0.860 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.500 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.400 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |